NCT05787327 is a Phase 2 clinical trial of Chinese Herb in COVID-19, sponsored by Chinese University of Hong Kong.

Who is sponsoring NCT05787327?

NCT05787327 is sponsored by Chinese University of Hong Kong.

What drugs are being tested in NCT05787327?

Interventions in NCT05787327: Chinese Herb, Placebo.

Is NCT05787327 still recruiting?

NCT05787327 is currently status unknown. Last updated 7 July 2023.

Last reviewed 2023-07-07 · How we verify

NCT05787327

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RCT for Yinqiaosan-Maxingganshitang in the Treatment of COVID-19

Status unknown Phase 2 Last updated 7 July 2023

What this trial tests

Phase 2 trial testing Chinese Herb in COVID-19 in 96 participants. Status unknown.

Timeline

25 May 2023

Primary endpoint
30 April 2024

30 September 2024

Quick facts

Lead sponsor	Chinese University of Hong Kong
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	96
Start date	25 May 2023
Primary completion	30 April 2024
Estimated completion	30 September 2024
Sites	1 location across Hong Kong

Drugs / interventions tested

Chinese Herb — full drug profile →
Placebo

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Chinese University of Hong Kong

Who can join

Adults 18 to 65, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized, double-blinded, placebo-controlled clinical trial. This study is to evaluate the effectiveness and safety of Yinqiaosan-Maxingganshitang in the treatment of the major symptoms of mild and moderate COVID-19 patients by telemedicine.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Chinese Herb

Trials testing the same drug.

NCT06393426 — The Constitution and Efficacy of Chinese Medicine of Infertility Male, Female, and Pregnant Female · completed
NCT04417101 — Chinese Herbal Medicine for Dialysis-related Myofascial Pain: Study Protocol for A Pilot Randomized Study · Phase 2 · unknown

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Chinese University of Hong Kong trials

Trials by the same sponsor.

NCT07508644 — RSV Vaccination to Reduce Recurrent AECOPD · Phase 4 · not yet recruiting
NCT07230457 — Plasma MTB cfDNA Before Bronchoscopy · not yet recruiting
NCT07288671 — Nostalgia Intervention on Alleviating Loneliness Amongst Older Adults · NA · not yet recruiting
NCT07256457 — Postoperative Pulmonary Function Assessment Based on Deep Learning Study · NA · not yet recruiting
NCT06904209 — Can Artificial Intelligence Reduce Consumption of Standard High Volume Bowel Preparation Regimen Among Older Population, · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05787327 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese University of Hong Kong
Last refreshed: 7 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05787327.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing